biotech · Lupus Nephritis - WHO Class III · Non Hodgkin Lymphoma · ARTV
Artiva Biotherapeutics
Artiva Biotherapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2019
- Employees
- 105
- Programs
- 8
- Drugs
- 9
- Patents
- 0
Artiva Biotherapeutics projects
5 ClinicalTrials.gov programs sponsored by Artiva Biotherapeutics.
Artiva Biotherapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AB-101
Artiva Biotherapeutics
Non Hodgkin Lymphoma
1 trial -
AB-101-05
Artiva Biotherapeutics
Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Sjögren’s Disease (SjD)
1 trial -
AB-201
Artiva Biotherapeutics
Breast Cancer
1 trial -
AFM13
Artiva Biotherapeutics
Relapsed or Refractory Hodgkin Lymphoma
1 trial -
Allogeneic NK Cells
Artiva Biotherapeutics
Refractory Rheumatoid Arthritis (RA)
1 trial
Frequently asked questions
How many clinical projects does Artiva Biotherapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.